US › Healthcare

Ginkgo Bioworks Holdings (DNA)

US · Healthcare · Biotechnology

$7.84+11.05%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$20.2M

Revenue YoY

-59.4%

Net profit

$-46.7M

EPS

$-0.86

EPS estimate

$-0.70

Net margin

-231.7%

EPS came in at -0.86 against a street estimate of -0.70 — a miss of 22.9%.

Key statistics

Market cap

$470.7M

Forward P/E

0.0

P/B

1.12

Book value

$6.60

EPS (TTM)

$-5.31

52-week high

$17.58

52-week low

$5.37

50-day MA

$7.78

200-day MA

$8.28

Beta

1.77

Analyst view

Analysts rate Ginkgo Bioworks Holdings a hold (1 buy, 1 hold, 4 sell out of 6) with an average price target of $7.00.

Shareholding

Insiders

4.43%

Institutions

73.70%

Largest institutional holders

Fund	Stake
BlackRock Inc	5.41%
Viking Global Investors LP	5.31%
Baillie Gifford & Co Limited.	3.55%
Erste Asset Management GmbH	2.89%
Vanguard Capital Management, LLC	2.84%
Anchorage Advisors, LLC	2.59%
Legal & General Group PLC	2.47%
State Street Corp	2.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ginkgo Bioworks Holdings — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.